News & Updates

Show Multimedia Only

Use of 5αRI does not increase cardiovascular risk in men with BPH

30 Sep 2023

Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.

Use of 5αRI does not increase cardiovascular risk in men with BPH

30 Sep 2023

Anabolic steroid use may lead to persistent sperm damage

30 Sep 2023

Most men with a history of anabolic steroid use have severe oligospermia, with only a few of them achieving normal semen parameters after 6 months of treatment, according to a study.

Anabolic steroid use may lead to persistent sperm damage

30 Sep 2023

Oral nalbuphine helps control moderate-to-severe pain after hemorrhoidectomy

29 Sep 2023

Treatment with the oral form of nalbuphine, PHN131, appears to effectively control moderate-to-severe pain in patients who have undergone hemorrhoidectomy, according to a study.

Oral nalbuphine helps control moderate-to-severe pain after hemorrhoidectomy

29 Sep 2023

Lorundrostat may expand treatment toolbox for uncontrolled hypertension

29 Sep 2023 by

Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.

Lorundrostat may expand treatment toolbox for uncontrolled hypertension

29 Sep 2023

Triple drug combo induces endoscopic remission in more than a third of CD patients

29 Sep 2023

In the treatment of Crohn’s disease (CD), the triple combination of vedolizumab, adalimumab, and methotrexate leads to endoscopic remission in 34.5 percent of patients and clinical remission in 54.5 percent, according to data from the phase IV EXPLORER trial.

Triple drug combo induces endoscopic remission in more than a third of CD patients

29 Sep 2023

Morning BP surge predicts visual field progression in glaucoma patients with hypertension

28 Sep 2023

Normal-tension glaucoma (NTG) patients with hypertension who experience morning blood pressure (BP) surge are likely to have visual field progression, as shown in a study.

Morning BP surge predicts visual field progression in glaucoma patients with hypertension

28 Sep 2023

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

28 Sep 2023 by

Tacrolimus given once daily significantly reduced the 3-year incidence of chronic lung allograft dysfunction (CLAD) in lung transplant patients compared with standard immunosuppressant in the open label, multicentre, ScanCLAD trial presented at ERS 2023.

Tacrolimus or cyclosporine for CLAD: The better of 2 immunosuppressants

28 Sep 2023

Is it safe to take mefenamic acid with ciprofol?

27 Sep 2023

Mefenamic acid shows no significant interaction with ciprofol in healthy individuals, which suggests that ciprofol is safe and well tolerated when administered along with mefenamic acid, reports a study.